Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$40.68 USD

40.68
846,040

-0.13 (-0.32%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $40.66 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

by Zacks Equity Research

Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

by Zacks Equity Research

Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

by Zacks Equity Research

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.

Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 92.31% and 77.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease

by Zacks Equity Research

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.

Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

by Zacks Equity Research

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX

by Kinjel Shah

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.

Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

by Zacks Equity Research

Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.

Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod

by Zacks Equity Research

FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate

by Kinjel Shah

FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.

Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka

by Zacks Equity Research

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.

Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise

by Zacks Equity Research

Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.